1. Clinical & Scientific Overview
Silodosin & Alfuzosin Hydrochloride IP (TIP-MED-000418, Reference Code [12.1]-CMP148) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relaxes Prostatic Smooth Muscle & Bladder Neck to Improve Urinary Flow).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Uroselective alpha-1A blocker comparators in BPH (Silodosin has dedicated monograph [12.8]).
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Uroselective alpha-1A blocker comparators in BPH (Silodosin has dedicated monograph [12.8]).
4. Therapeutic Indications & Evidence-Supported Uses
- Functional lower urinary tract symptoms (LUTS: urinary hesitancy, weak stream, incomplete emptying, nocturia) associated with Benign Prostatic Hyperplasia (BPH)
- medical expulsive therapy (MET) to facilitate spontaneous passage of distal ureteric calculi (<8–10 mm kidney stones)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Uroselective alpha-1A blocker comparators in BPH (Silodosin has dedicated monograph [12.8]).
Administration & Meal Timing: MUST be taken 30 minutes AFTER the same meal every day (typically 30 minutes after Dinner)! NEVER take on an empty stomach! (Taking tamsulosin on an empty stomach increases oral bioavailability by 30% and increases peak plasma concentration [Cmax] by 40% to 70%, causing precipitous postural hypotension, dizziness, and fainting!). Swallow MR capsule/tablet whole—do NOT crush, chew, or open! | Once daily in the evening (30 minutes after dinner / before bedtime).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [12.1].
Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
7. Contraindications, Precautions & High-Risk Warnings
- 1. MANDATORY CATARACT SURGERY WARNING — INTRAOPERATIVE FLOPPY IRIS SYNDROME (IFIS)! Tamsulosin (and Silodosin/Alfuzosin) binds avidly and semi-permanently to Alpha-1A receptors in the iris dilator muscle! During phacoemulsification cataract surgery, this causes a triad of billowing floppy iris, progressive intraoperative pupil constriction, and iris prolapse through surgical incisions—risking posterior capsule rupture and vision loss! Even if stopped weeks or months before cataract surgery, IFIS can still occur—the ophthalmic surgeon MUST be informed in advance so iris hooks/phenylephrine can be prepared, and starting tamsulosin newly in a patient awaiting imminent cataract surgery should be deferred until after surgery! 2. Contraindicated in history of orthostatic syncope and severe hepatic failure.
Key Clinical Precautions: Renal: Excreted <10% unchanged in urine—no dose adjustment required in mild-to-severe CKD (down to CrCl 10 mL/min). Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
8. Adverse Effects Profile
- Orthostatic dizziness / postural lightheadedness (especially after the first dose or upon standing up at night to urinate!), abnormal ejaculation / retrograde ejaculation into the bladder (8–18% with Tamsulosin; >28% with Silodosin—harmless but alarming if unwarned!), nasal congestion/rhinitis (nasal turbinate alpha-1 vasodilation), headache.
- First-Dose Orthostatic Syncope and Hip-Fracture Falls, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism (extremely rare), Stevens-Johnson syndrome (rare).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- PDE-5 Inhibitors (Sildenafil, Tadalafil, Vardenafil) & Other Alpha-Blockers (Prazosin, Terazosin, Carvedilol): Profound additive vasodilation and symptomatic hypotension! (Never combine two alpha-blockers, and space PDE-5 inhibitors by ≥4–6 hours)
- Potent CYP3A4 & CYP2D6 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Paroxetine, Fluoxetine, Terbinafine, Cimetidine): Increase tamsulosin plasma exposure 2- to 3-fold (causing severe postural syncope!)
- Antihypertensives & Loop Diuretics: Additive postural blood pressure drop
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.1].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 3 Non-Negotiable Counter Warnings for Urimax / Veltam: 1. The '30 Minutes After Dinner & Sit Before Standing' Rule: Always swallow the capsule whole 30 minutes after dinner. When waking up at night to pass urine (especially during the first week), sit on the edge of the bed for 60 seconds and dangle your legs before standing up so you do not faint on the bathroom floor! 2. Cataract Surgery Alert: Ask every elderly patient: 'Are you planning Motiyabind (cataract) eye surgery in the coming months?' Tell them they MUST inform their eye surgeon that they take Urimax/Veltam! 3. Reassure that stuffy nose or reduced semen volume during ejaculation is a benign muscle-relaxing effect.
- Meal & Clock Timing Instruction: MUST be taken 30 minutes AFTER the same meal every day (typically 30 minutes after Dinner)! NEVER take on an empty stomach! (Taking tamsulosin on an empty stomach increases oral bioavailability by 30% and increases peak plasma concentration [Cmax] by 40% to 70%, causing precipitous postural hypotension, dizziness, and fainting!). Swallow MR capsule/tablet whole—do NOT crush, chew, or open! (Once daily in the evening (30 minutes after dinner / before bedtime).)
- Missed Dose Protocol: Take 30 minutes after the next meal on the same day; if missed for several consecutive days, restart 30 minutes after dinner with bedtime postural precautions.
- Geriatric Dispensing Pearl: While tamsulosin is much more uroselective than older non-selective alpha-blockers (Prazosin [Prazopress] or Terazosin [Hytrin], which are flagged in Beers Criteria), night-time bathroom falls remain a major hazard when elderly men combine Tamsulosin with antihypertensives or diuretics.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Modified-Release (MR) Capsules / Tablets: 0.4 mg (400 mcg) (also 0.2 mg in select brands)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.3] Solifenacin Succinate — Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anti
- [12.4] Mirabegron — Selective Beta-3 Adrenoceptor Agonist (Relaxes Detrusor Smooth Mu
- [12.8] Silodosin (Uroselective Alpha-1A Blocker for BPH) — Highly Uroselective Alpha-1A Adrenergic Receptor Antagonist
- [12.9] Dutasteride (Dual Type-1/Type-2 5-Alpha-Reductase Inhibitor) — Dual Type-1 and Type-2 5-Alpha-Reductase Inhibitor